Table 1.
Demographics and clinical characteristics of the patients stratified by psoriasis presence.
| Median (IQR) | |||
|---|---|---|---|
| Psoriasis (n = 122) | No psoriasis (n = 134) | P | |
| Age, years | 44.5 (34–57) | 49 (44–54) | 0.01 |
| Male, n (%) | 68 (60) | 71 (53) | 0.29 |
| Hypertension, n (%) | 39 (35) | 27 (20) | 0.01 |
| Current smoker, n (%) | 8 (7) | 0 (0) | 0.001 |
| Waist size, inches | 40 (35–44) | 35.5 (33–39.5) | < 0.001 |
| BMI, kg/m2 | 29.5 (25.9–33.4) | 26.9 (24.9–30.1) | 0.001 |
| Diabetes mellitus, n (%) | 10 (8.8) | 5 (3.7) | 0.1 |
| CRP, mg/L | 3.3 (.835–9.85) | 1.3 (0.6–2.4) | 0.02 |
| Fasting glucose, mg/dL, n | 88 | 90 | 0.19 |
| Insulin, µU/mL, n (%) | 17.7 | 6.3 | < 0.001 |
| HOMA-IR | 3.5 (2.3–6.6) | 1.4 (.9–2.1) | < 0.001 |
| Total cholesterol, mg/dL | 186 (164–218) | 208.5 (189–231) | < 0.001 |
| LDL (mg/dL) | 106.9 (90–132.5) | 130 (106.4–147.4) | < 0.001 |
| HDL (mg/dL) | 43 (36–58) | 49 (42–62) | < 0.01 |
| Triglycerides (mg/dL) | 127 (78–190) | 130 (91–159) | 0.95 |
| Currently on LLT | 19 (16%) | 22 (16%) | 0.31 |
| Psoriasis severity (% BSA) | 2.9 (1–8.5) | NA | |
| Psoriasis treatment, n (%) | |||
| Topical only | 71 (58) | NA | NA |
| Systemic | 12 (9) | NA | NA |
| Phototherapy | 11 (9) | NA | NA |
BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; LLT, lipid-lowering therapy; NA, not applicable. All data are mean (range) unless otherwise stated.